Revance Therapeutics Inc (NASDAQ: RVNC) started the day on Wednesday, remained unchanged at $5.29, before settling in for the price of $5.29 at the close. Taking a more long-term approach, RVNC posted a 52-week range of $2.30-$9.74.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The company of the Healthcare sector’s yearbook sales growth during the past 5- year span was recorded 815.27%. Meanwhile, its Annual Earning per share during the time was 0.57%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 50.79%. This publicly-traded company’s shares outstanding now amounts to $104.18 million, simultaneously with a float of $95.08 million. The organization now has a market capitalization sitting at $551.11 million.
Revance Therapeutics Inc (RVNC) Ownership Facts and Figures
Now let’s turn our focus to how large-scale investors are working with this stock of the Biotechnology Industry. Revance Therapeutics Inc’s current insider ownership accounts for 8.74%, in contrast to 71.60% institutional ownership. According to the most recent insider trade that took place on Apr 16 ’24, this organization’s Chief Commercial Officer sold 2,392 shares at the rate of 3.80, making the entire transaction reach 9,096 in total value, affecting insider ownership by 114,864. Preceding that transaction, on Mar 18 ’24, Company’s President sold 9,211 for 5.04, making the whole transaction’s value amount to 46,446. This particular insider is now the holder of 167,550 in total.
Revance Therapeutics Inc (RVNC) Earnings and Revenue Records
Revance Therapeutics Inc’s EPS increase for this current 12-month fiscal period is 50.79% and is forecasted to reach -0.50 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 11.60% through the next 5 years, which can be compared against the 0.57% growth it accomplished over the previous five years trading on the market.
Revance Therapeutics Inc (NASDAQ: RVNC) Trading Performance Indicators
Let’s observe the current performance indicators for Revance Therapeutics Inc (RVNC). It’s Quick Ratio in the last reported quarter now stands at 3.01. The Stock has managed to achieve an average true range (ATR) of 0.19. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 2.26.
In the same vein, RVNC’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -3.19, a figure that is expected to reach -0.27 in the next quarter, and analysts are predicting that it will be -0.50 at the market close of one year from today.
